Improving Outcomes in Patients with ITP
|Improving Outcomes for Pediatric and Adult Patients with Immune Thrombocytopenia|
CME, CPE, CNE
Hanny Al-Samkari, MD and Michele P. Lambert, MD, MSTR
|Release Date: February 10, 2023|
Expiration Date: February 10, 2024
The overall goal of immune thrombocytopenia (ITP) treatment is to reduce platelet and megakaryocyte destruction via immune modulation or splenectomy, or to increase megakaryocyte platelet production via thrombopoietin receptor agents. To facilitate treatment decisions, it is critical that adult and pediatric clinicians are knowledgeable about ITP pathophysiology. In this activity, two experts will discuss pediatric and adult treatment options, guideline recommendations and evidence supporting best practice, and strategies for engaging in shared decision-making.Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from UCB, Inc.
|Begin, Earn CreditView Only, No Credit|